Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?

키워드

참고문헌 (157)

1. Craig AJ, "Tumour evolution in hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 17, pp.139~152 (2020)
2. Ringelhan M, "The immunology of hepatocellular carcinoma", Nat Immunol, 19, pp.222~232 (2018)
3. Zheng L, "Comparative effectiveness of radiofrequency ablation vs. surgical resection for patients with solitary hepatocellular carcinoma smaller than 5 cm", Front Oncol, 10, pp.399~ (2020)
4. Llovet JM, "Molecular therapies and precision medicine for hepatocellular carcinoma", Nat Rev Clin Oncol, 15, pp.599~616 (2018)
5. Finn RS, "Pembrolizumab as secondline therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, double-blind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
6. Finn RS, "Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma", J Clin Oncol, 38, pp.2960~2970 (2020)
7. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
8. Zongyi Y, "Immunotherapy for hepatocellular carcinoma", Cancer Lett, 470, pp.8~17 (2020)
9. Peeraphatdit TB, "Hepatotoxicity from immune checkpoint inhibitors : a systematic review and management recommendation", Hepatology, 72, pp.315~329 (2020)
10. Murray PJ, "Macrophage activation and polarization : nomenclature and experimental guidelines", Immunity, 41, pp.14~20 (2014)
11. Martinez FO, "The M1 and M2 paradigm of macrophage activation : time for reassessment", F1000Prime Rep, 6, pp.13~ (2014)
12. Zhou D, "Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways", Cell Signal, 26, pp.192~197 (2014)
13. Mantovani A, "The chemokine system in diverse forms of macrophage activation and polarization", Trends Immunol, 25, pp.677~686 (2004)
14. Krenkel O, "Liver macrophages in tissue homeostasis and disease", Nat Rev Immunol, 17, pp.306~321 (2017)
15. Sica A, "Macrophage plasticity and polarization in liver homeostasis and pathology", Hepatology, 59, pp.2034~2042 (2014)
16. Prieto J, "Immunological landscape and immunotherapy of hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 12, pp.681~700 (2015)
17. Cariani E, "Immune landscape of hepatocellular carcinoma microenvironment : implications for prognosis and therapeutic applications", Liver Int, 39, pp.1608~1621 (2019)
18. Sharma P, "Primary, adaptive, and acquired resistance to cancer immunotherapy", Cell, 168, pp.707~723 (2017)
19. Genard G, "Reprogramming of tumorassociated macrophages with anticancer therapies : radiotherapy versus chemo-and immunotherapies", Front Immunol, 8, pp.828~ (2017)
20. Xu G, "Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization", Oncogene, 39, pp.1429~1444 (2020)
21. Thorsson V, "The immune landscape of cancer", Immunity, 48, pp.812~830 (2018)
22. Hilmi M, "Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma : current knowledge and future research directions", J Immunother Cancer, 7, pp.333~ (2019)
23. Dong LQ, "Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma", J Hepatol, 72, pp.896~908 (2020)
24. Zhang Q, "Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas", Gut, 68, pp.2019~2031 (2019)
25. Cassetta L, "Tumor-associated macrophages", Curr Biol, 30, pp.R246~ (2020)
26. Pathria P, "Targeting tumor-associated macrophages in cancer", Trends Immunol, 40, pp.310~327 (2019)
27. Tacke F, "Macrophage heterogeneity in liver injury and fibrosis", J Hepatol, 60, pp.1090~1096 (2014)
28. Starkey Lewis PJ, "Macrophages as a cellbased therapy for liver disease", Semin Liver Dis, 39, pp.442~451 (2019)
29. Luedde T, "NF-κB in the liver : linking injury, fibrosis and hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 8, pp.108~118 (2011)
30. Lee SR, "Dietary intake of genistein suppresses hepatocellular carcinoma through AMPK-mediated apoptosis and anti-inflammation", BMC Cancer, 19, pp.6~ (2019)
31. Miura K, "Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet", Cancer Sci, 110, pp.771~783 (2019)
32. Zhao X, "Nogo-B fosters HCC progression by enhancing Yap", Taz-mediated tumor-associated macrophages M2 polarization, 2020, pp.391, 111979~
33. Zhou TY, "Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumorassociated macrophages", J Pharmacol Sci, 138, pp.89~95 (2018)
34. Li Z, "SIRT4 silencing in tumor-associated macrophages promotes HCC development via PPARδsignalling-mediated alternative activation of macrophages", J Exp Clin Cancer Res, 38, pp.469~ (2019)
35. Zhang W, "Depletion of tumorassociated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects", Clin Cancer Res, 16, pp.3420~3430 (2010)
36. Tan HY, "Autophagy-induced RelB", p52 activation mediates tumourassociated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin, 2015, pp.6, e1942~
37. Chen S, "Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma", J Cell Physiol, 233, pp.5002~5013 (2018)
38. Esteller M, "Non-coding RNAs in human disease", Nat Rev Genet, 12, pp.861~874 (2011)
39. Li Z, "GNAS-AS1", miR-4319, Funct Integr Genomics, pp.2020, 20[DOI]
40. Poles WA, "Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly", Cancer Immunol Immunother, 68, pp.269~282 (2019)
41. Pea A, "Biology and clinical application of regulatory RNAs in hepatocellular carcinoma", Hepatology, 73(Suppl 1), pp.38~48 (2021)
42. Frión-Herrera Y, "Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells", Life Sci, 235, pp.116817~ (2019)
43. Mondal S, "Matrix metalloproteinase-9(MMP-9)and its inhibitors in cancer : a minireview", Eur J Med Chem, 194, pp.112260~ (2020)
44. Liu G, "M2 macrophages promote HCC cells invasion and migration via miR149-5p", MMP9 signaling, 2020, pp.11, 1277~1287
45. Bayraktar R, "miR-155 in cancer drug resistance and as target for miRNA-based therapeutics", Cancer Metastasis Rev, 37, pp.33~44 (2018)
46. Zhang L, "MicroRNA-155 promotes tumor growth of human hepatocellular carcinoma by targeting ARID2", Int J Oncol, 48, pp.2425~2434 (2016)
47. Ye Y, "Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1", M2 macrophage polarization, 2018, pp.119, 2951~2963
48. Yin C, "SALL4-mediated upregulation of exosomal miR-146a-5p drives T-cell exhaustion by M2 tumor-associated macrophages in HCC", Oncoimmunology, 8, pp.1601479~ (2019)
49. Li X, "Regulation of macrophage activation and polarization by HCC-derived exosomal lncRNA TUC339", Int J Mol Sci, 19, pp.2958~ (2018)
50. Wang Y, "miR-125a", b inhibits tumor-associated macrophages mediated in cancer stem cells of hepatocellular carcinoma by targeting CD90, 2019, pp.120, 3046~3055
51. Fan DN, "Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b", Hepatology, 57, pp.637~647 (2013)
52. Zhou SL, "miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis", Hepatology, 63, pp.1560~1575 (2016)
53. Ke M, "MicroRNA-148b-colonystimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis", Biomed Pharmacother, 120, pp.109523~ (2019)
54. Hu ZQ, "Circular RNA sequencing identifies circASAP1 as a key regulator in hepatocellular carcinoma metastasis", Hepatology, 72, pp.906~922 (2020)
55. Ye Y, "Macrophages-induced long noncoding RNA H19 up-regulation triggers and activates the miR-193b", MAPK1 axis and promotes cell aggressiveness in hepatocellular carcinoma, 2020, pp.469, 310~322
56. Li X, "Casticin inhibits stemness of hepatocellular carcinoma cells via disrupting the reciprocal negative regulation between DNMT1 and miR-148a-3p", Toxicol Appl Pharmacol, 396, pp.114998~ (2020)
57. Xiong L, "Aberrant enhancer hypomethylation contributes to hepatic carcinogenesis through global transcriptional reprogramming", Nat Commun, 10, pp.335~ (2019)
58. Yang L, "Upregulation of CEP55predicts dismal prognosis in patients with liver cancer", Biomed Res Int, 2020, pp.4139320~ (2020)
59. Ng KT, "Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma", Mol Cancer, 13, pp.196~ (2014)
60. Lu Y, "Type conversion of secretomes in a 3D TAM2 and HCC cell co-culture system and functional importance of CXCL2 in HCC", Sci Rep, 6, pp.24558~ (2016)
61. Jun Ding, "Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma", BMB Reports, 51(12), pp.630~635 (2018), 생화학분자생물학회
62. Subat S, "Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma", J Cancer Res Clin Oncol, 145, pp.675~684 (2019)
63. Zhou Y, "LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8", ID2 pathway in hepatocellular carcinoma, 2020, pp.469, 399~409
64. de Oliveira FL, "Galectin-3, histone deacetylases, and Hedgehog signaling : possible convergent targets in schistosomiasis-induced liver fibrosis", PLoS Negl Trop Dis, 11, pp.e0005137~ (2017)
65. Fan Z, "The histone methyltransferase SUV39h2 contributes to nonalcoholic steatohepatitis in mice", Hepatology, 65, pp.1904~1919 (2017)
66. Tikhanovich I, "Arginine methylation regulates c-Myc-dependent transcription by altering promoter recruitment of the acetyltransferase p300", J Biol Chem, 292, pp.13333~13344 (2017)
67. Tikhanovich I, "Protein arginine methyltransferase 1 modulates innate immune responses through regulation of peroxisome proliferator-activated receptor γ-dependent macrophage differentiation", J Biol Chem, 292, pp.6882~6894 (2017)
68. Zhao J, "PRMT1-dependent macrophage IL-6 production is required for alcohol-induced HCC progression", Gene Expr, 19, pp.137~150 (2019)
69. Yu S, "Autophagy in the"inflammationcarcinogenesis"pathway of liver and HCC immunotherapy", Cancer Lett, 411, pp.82~89 (2017)
70. Wei Y, "Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes hepatoma progression in mice", Gastroenterology, 156, pp.1890~1904 (2019)
71. Yin Y, "EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment", J Neuroinflammation, 14, pp.220~ (2017)
72. Chassaing B, "Microbiotaliver axis in hepatic disease", Hepatology, 59, pp.328~339 (2014)
73. Ponziani FR, "Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease", Hepatology, 69, pp.107~120 (2019)
74. Kumar V, "Toll-like receptors in the pathogenesis of neuroinflammation", J Neuroimmunol, 332, pp.16~30 (2019)
75. West AP, "TLR signalling augments macrophage bactericidal activity through mitochondrial ROS", Nature, 472, pp.476~480 (2011)
76. Li W, "STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma", J Clin Invest, 125, pp.4239~4254 (2015)
77. Yu LX, "The gut microbiome and liver cancer : mechanisms and clinical translation", Nat Rev Gastroenterol Hepatol, 14, pp.527~539 (2017)
78. Dapito DH, "Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4", Cancer Cell, 21, pp.504~516 (2012)
79. Miura K, "Toll-like receptor 4 on macrophage promotes the development of steatohepatitisrelated hepatocellular carcinoma in mice", J Biol Chem, 291, pp.11504~11517 (2016)
80. Zheng Y, "Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma", J Immunother Cancer, 7, pp.193~ (2019)
81. Wan MLY, "Targeting gut microbiota in hepatocellular carcinoma : probiotics as a novel therapy", Hepatobiliary Surg Nutr, 7, pp.11~20 (2018)
82. Li J, "Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice", Proc Natl Acad Sci U S A, 113, pp.E1306~ (2016)
83. Golfieri R, "Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma", Br J Cancer, 111, pp.255~264 (2014)
84. Salimon M, "Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma : an AGEO French multicentre retrospective study", Br J Cancer, 118, pp.325~330 (2018)
85. Sangiovanni A, "Treatment of hepatocellular carcinoma : beyond international guidelines", Liver Int, 36(Suppl 1), pp.124~129 (2016)
86. Liu Z, "Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma", J Exp Clin Cancer Res, 38, pp.447~ (2019)
87. Teufel M, "Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma", Gastroenterology, 156, pp.1731~1741 (2019)
88. Hu B, "KPNA3 confers sorafenib resistance to advanced hepatocellular carcinoma via TWIST regulated epithelial-mesenchymal transition", J Cancer, 10, pp.3914~3925 (2019)
89. Lin Z, "RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy", EMBO J, 39, pp.e103181~ (2020)
90. Song Z, "HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib", Cancer Lett, 460, pp.96~107 (2019)
91. Xue ST, "The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target", Autophagy, 16, pp.1823~1837 (2020)
92. Fu XT, "Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma", Cancer Cell Int, 19, pp.71~ (2019)
93. Guo B, "M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma", Oncotarget, 8, pp.44465~44476 (2017)
94. Song Y, "Self-enforcing HMGB1", NF-κB, J Cancer, pp.2020, 11[DOI]
95. Jiang J, "Hypoxia-induced HMGB1 expression of HCC promotes tumor invasiveness and metastasis via regulating macrophagederived IL-6", Exp Cell Res, 367, pp.81~88 (2018)
96. Zhang QB, "High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis", BMC Cancer, 16, pp.880~ (2016)
97. Zhang J, "Hypoxia-inducible factor1α", interleukin-1β signaling enhances hepatoma epithelialmesenchymal transition through macrophages in a hypoxicinflammatory microenvironment, 2018, pp.67, 1872~1889
98. Weng YS, "MCT-1", miR-34a, IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer, pp.Mol Cancer, 2019[DOI]
99. Yin Z, "IL-6", STAT3 pathway intermediates M1, J Cell Biochem, pp.2018, 119[DOI]
100. Fu XT, "Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2", STAT3, Int J Oncol, pp.2015, 46[DOI]
101. Zhong CQ, "FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma", Cancer Med, 7, pp.2629~2640 (2018)
102. Huber R, "Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages", Sci Rep, 6, pp.29914~ (2016)
103. Fan QM, "Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma", Cancer Lett, 352, pp.160~168 (2014)
104. Deng G, "The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma", Sci Rep, 7, pp.41616~ (2017)
105. Dong N, "M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma", Br J Cancer, 121, pp.22~33 (2019)
106. Li X, "Targeting of tumour-infiltrating macrophages via CCL2", CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma, 2017, pp.66, 157~167
107. Yao W, "A natural CCR2 antagonist relieves tumor-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer", EBioMedicine, 22, pp.58~67 (2017)
108. Sadeghi M, "Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma", Br J Cancer, 113, pp.756~762 (2015)
109. Wang T, "Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumorlocalized chemoimmunotherapy", Nanoscale, 11, pp.13934~13946 (2019)
110. Kimura T, "Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model", Cancer Sci, 109, pp.3993~4002 (2018)
111. Yang Y, "Compound Kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib", J Immunother Cancer, 8, pp.e000317~ (2020)
112. Zhou SL, "Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib", Gastroenterology, 150, pp.1646~1658 (2016)
113. Yu Y, "Radiotherapy for hepatocellular carcinoma", Semin Radiat Oncol, 28, pp.277~287 (2018)
114. Giganti F, "Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and(18)F-FDG-PET", CT : correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade, 2014, pp.40, 1147~1157
115. Chung YH, "Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model : timeline validation", Eur J Nucl Med Mol Imaging, 46, pp.1733~1744 (2019)
116. Ding T, "High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection", Hum Pathol, 40, pp.381~389 (2009)
117. Jeong KY, "Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma", J Radiat Res, 56, pp.37~45 (2015)
118. Coscia M, "Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway", J Cell Mol Med, 14, pp.2803~2815 (2010)
119. Morii K, "Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma", Intern Med, 54, pp.2609~2613 (2015)
120. Zhou DY, "Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models", Oncol Lett, 14, pp.4078~4084 (2017)
121. Choi J, "A prospective phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers", J Radiat Res, 60, pp.242~248 (2019)
122. Choi C, "Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma", World J Gastroenterol, 25, pp.2416~2429 (2019)
123. Kim HJ, "Clinical significance of soluble programmed cell death ligand-1(sPD-L1)in hepatocellular carcinoma patients treated with radiotherapy", Radiother Oncol, 129, pp.130~135 (2018)
124. Chen J, "Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas", Cancer Immunol Immunother, 61, pp.101~108 (2012)
125. Qasim W, "Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient", J Hepatol, 62, pp.486~491 (2015)
126. Liu P, "Natural killer cells in liver disease and hepatocellular carcinoma and the NK cell-based immunotherapy", J Immunol Res, 2018, pp.1206737~ (2018)
127. Sasidharan Nair V, "DNA methylation and repressive H3K9 and H3K27trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer", Clin Epigenetics, 10, pp.78~ (2018)
128. Cristescu R, "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy", Science, 362, pp.eaar3593~ (2018)
129. Kudo M, "Combination cancer immunotherapy in hepatocellular carcinoma", Liver Cancer, 7, pp.20~27 (2018)
130. Wu X, "Application of PD-1 blockade in cancer immunotherapy", Comput Struct Biotechnol J, 17, pp.661~674 (2019)
131. Gu Y, "CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma", Aging(Albany NY), 12, pp.784~807 (2020)
132. Li G, "Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice", Gastroenterology, 154, pp.1024~1036 (2018)
133. Shi F, "PD-1 and PD-L1 upregulation promotes CD8(+)T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients", Int J Cancer, 128, pp.887~896 (2011)
134. Gordon SR, "PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity", Nature, 545, pp.495~499 (2017)
135. Yagi T, "Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer", Eur J Cancer, 111, pp.38~49 (2019)
136. Gok Yavuz B, "Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1 +TAMs", Sci Rep, 9, pp.3172~ (2019)
137. Liu J, "Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and upregulate programmed death ligand 1 expression in macrophages", Hepatology, 70, pp.241~258 (2019)
138. Zhu Y, "Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colonystimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade", Gut, 68, pp.1653~1666 (2019)
139. Han Z, "Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses", Cancer Immunol Immunother, 68, pp.1073~1085 (2019)
140. Liu J, "Implication of myeloid differentiation factor 88 inhibitor TJ-M2010-5 for therapeutic intervention of hepatocellular carcinoma", Hepatol Res, 49, pp.1182~1194 (2019)
141. Llopiz D, "Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model", Cancer Immunol Immunother, 68, pp.379~393 (2019)
142. Zong Z, "M1 Macrophages induce PD-L1expression in hepatocellular carcinoma cells through IL-1βsignaling", Front Immunol, 10, pp.1643~ (2019)
143. Noy R, "Tumor-associated macrophages : from mechanisms to therapy", Immunity, 41, pp.49~61 (2014)
144. Lin C, "Tumour-associated macrophagesderived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer", Gut, 68, pp.1764~1773 (2019)
145. Jansen CS, "An intratumoral niche maintains and differentiates stem-like CD8 T cells", Nature, 576, pp.465~470 (2019)
146. Peranzoni E, "Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment", Proc Natl Acad Sci U S A, 115, pp.E4041~ (2018)
147. Ma J, "PD1 Hi CD8 + T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma", J Immunother Cancer, 7, pp.331~ (2019)
148. Weiskopf K, "CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer", J Clin Invest, 126, pp.2610~2620 (2016)
149. Xiao Z, "Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma", Cancer Lett, 360, pp.302~309 (2015)
150. Lo J, "Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma", Liver Int, 36, pp.737~745 (2016)
151. de Oliveira Matos A, "The role of the triggering receptor expressed on myeloid cells-1(TREM-1)in non-bacterial infections", Crit Rev Microbiol, 46, pp.237~252 (2020)
152. Campbell GR, "TREM-1protects HIV1-infected macrophages from apoptosis through maintenance of mitochondrial function", mBio, 10, pp.e02638~ (2019)
153. Wu Q, "Blocking triggering receptor expressed on myeloid cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer", Hepatology, 70, pp.198~214 (2019)
154. Chen Y, "CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice", Hepatology, 61, pp.1591~1602 (2015)
155. Yu S, "Tumor-infiltrating immune cells in hepatocellular carcinoma : Tregs is correlated with poor overall survival", PLoS One, 15, pp.e0231003~ (2020)
156. Khemlina G, "The biology of hepatocellular carcinoma : implications for genomic and immune therapies", Mol Cancer, 16, pp.149~ (2017)
157. Li Z, "Individualized precision treatment : targeting TAM in HCC", Cancer Lett, 458, pp.86~91 (2019)

관련 논문AI추천